skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Infliximab for the treatment of plaque psoriasis

Review

(3151) Views  (430) Full article downloads

Authors: Jennifer S Gall, Robert E Kalb

Published Date March 2008 Volume 2008:2(1) Pages 115 - 124
DOI: http://dx.doi.org/10.2147/BTT.S2116

Jennifer S Gall, Robert E Kalb

State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Department of Dermatology, NY, USA

Abstract: Infliximab is a monoclonal antibody that targets tumor necrosis factor-α (TNFα). It is used in the treatment of a number of inflammatory disorders including severe plaque psoriasis. TNFα is thought to have a major role in psoriasis by promoting an inflammatory infiltrate into the skin and inducing keratinocyte proliferation and preventing keratinocyte apoptosis, which directly contributes to the characteristic plaque skin lesions. Based on four randomized, placebo-controlled, double-blind clinical trials and nine open-label uncontrolled trials of the use of infliximab in plaque psoriasis, it was found that infliximab is a highly efficacious, rapid, sustainable, and relatively safe therapy. Yet as with any biologic, caution is recommended in its use as infusion reactions, lupus-like syndromes, infections, malignancies including lymphomas, as well as other rare events have been reported.

Keywords: infliximab, psoriasis, plaque






 

Other articles by Dr Robert Kalb



Readers of this article also read:

A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers
The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia
α-L-iduronidase therapy for mucopolysaccharidosis type I
Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy
Therapeutic vaccines for malignant brain tumors
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
Abatacept in difficult-to-treat juvenile idiopathic arthritis
Periosteoplasty for covering gingival recessions: Clinical results
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed